Maxim Group Remains Bullish on Celsion (CLSN) Following Announced Phase lll OPTIMA Study
Get Alerts CLSN Hot Sheet
Rating Summary:
5 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Maxim Group reiterated a Buy rating and $9.00 price target on Celsion Corp (NASDAQ: CLSN) following the company's announced phase III OPTIMA study of lead compound ThermoDox.
Analyst Jason McCarthy commented, "Celsion announced that the phase III OPTIMA study of lead compound ThermoDox (heat-activated liposomal doxorubicin) for the treatment of primary liver cancer was highlighted in an oral presentation at the 7th AsiaPacific Primary Liver Cancer Expert ("APPLE") Meeting."
For an analyst ratings summary and ratings history on Celsion Corp click here. For more ratings news on Celsion Corp click here.
Shares of Celsion Corp closed at $1.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
- CACI International (CACI) PT Raised to $440 at Stifel
- Sage Therapeutics (SAGE) PT Lowered to $18 at Truist Securities
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Maxim GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!